Mitochondrial Health

Fisetin Bioavailability: Why Formulation Matters

Written by ReCellence™ Editorial Team, Health Content SpecialistsReviewed by Medical Review Board, MD, PhDLast reviewed: March 8, 2026

Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.

What This Page Explains

Bioavailability — the fraction of an ingested substance that reaches systemic circulation — is one of the most significant challenges in fisetin research. Like many flavonoids, fisetin has very low oral bioavailability, which raises fundamental questions about whether oral supplementation can achieve the tissue concentrations shown to be active in cell culture experiments.

Your Cells Replace Themselves Every 7–10 Years. The Question Is: With What?

The raw materials you give your body today determine the quality of every new cell. Make each one count.

Detailed Evidence

In cell culture experiments, fisetin has shown senolytic and anti-inflammatory effects at concentrations of 10–100 micromolar (μM). However, after oral administration in animal studies, peak plasma concentrations are typically in the low micromolar to nanomolar range — potentially 10–100× lower than effective in vitro concentrations. When fisetin is consumed orally, it undergoes extensive first-pass metabolism in the intestinal wall and liver. Phase II metabolism (glucuronidation and sulfation) rapidly converts fisetin into conjugated metabolites. The estimated oral bioavailability of standard fisetin is below 10%. Researchers are exploring several approaches to improve fisetin bioavailability: liposomal formulations (3–5× improvement), nanoparticle-based systems (4–10× improvement), and co-crystallization techniques.

Evidence Hierarchy

Strongest

Systematic Reviews & Meta-Analyses

Multiple high-quality trials combined

Strong

Randomized Controlled Trials (RCTs)

Gold standard for treatment efficacy

Moderate

Observational Studies

Can show associations, not causation

Limited

Case Reports & Expert Opinion

Hypothesis-generating only

Weakest

Preclinical (Lab/Animal) Studies

Should NOT be extrapolated to humans

If You're Over 45 And Tired of Feeling Tired, Read This

Most people blame aging for their energy crash. The real culprit? Dysfunctional mitochondria. There's a science-backed solution.

Study Quality Indicators

Higher Quality Indicators

  • Large sample size (hundreds to thousands)
  • Randomized and blinded design
  • Placebo-controlled comparison
  • Published in peer-reviewed journals
  • Replicated in multiple studies
  • Registered trial protocol before starting

Lower Quality Indicators

  • Small sample size (under 100)
  • No control group or blinding
  • Manufacturer-funded with conflicts
  • Only animal/cell studies
  • Never replicated
  • Published in predatory journals

Important Limitations

  • • Supplement research often has methodological limitations
  • • Results from one study may not generalize to all people
  • • Marketing claims often exceed what research supports
  • • Absence of evidence is not evidence of absence
  • • Individual response to supplements varies widely

Quick Answers

Q1.

What is fisetin's bioavailability?

Fisetin's oral bioavailability is estimated at less than 10% due to poor water solubility and rapid hepatic metabolism.

Q2.

Why is fisetin bioavailability important?

Low bioavailability means oral supplements may not achieve the tissue concentrations shown to be effective in cell culture studies (10–100 μM).

Q3.

Is liposomal fisetin better absorbed?

Animal studies suggest liposomal formulations may improve bioavailability by 3–5×, but human data is lacking.

Q4.

What is first-pass metabolism?

First-pass metabolism is the breakdown of compounds in the intestinal wall and liver before they reach systemic circulation.

Q5.

Are fisetin metabolites active?

It is unknown whether fisetin metabolites (glucuronides, sulfates) retain meaningful senolytic or anti-inflammatory activity.

Q6.

Can piperine improve fisetin absorption?

Piperine may inhibit glucuronidation enzymes (as with curcumin), but this has not been validated for fisetin specifically.

Q7.

What is BCS Class IV?

BCS Class IV compounds have low solubility and low permeability — the most challenging category for oral drug delivery.

Q8.

Does taking fisetin with fat help?

No specific food-effect studies have been published for fisetin, though fat may theoretically improve absorption of lipophilic compounds.

Q9.

How long does fisetin stay in the body?

Fisetin is rapidly metabolized and eliminated. Specific half-life data in humans has not been published.

Q10.

What formulations improve fisetin absorption?

Liposomal, nanoparticle (PLGA, chitosan, solid lipid), and amorphous solid dispersions show promise in animal studies.

Q11.

Is nano fisetin better?

Nanoparticle-based delivery systems showed 4–10× bioavailability improvements in animal models, but human validation is lacking.

Q12.

Does bioavailability differ between brands?

Different supplements use different formulations with potentially very different bioavailability profiles, but no standardized testing exists.

Q13.

Can fisetin be given by injection?

Injectable fisetin has been used in animal research but is not available for human use.

Q14.

How does fisetin bioavailability compare to quercetin?

Both flavonoids have poor oral bioavailability (<10%). Quercetin has been more extensively studied with various enhancement strategies.

Q15.

Will bioavailability improve with new formulations?

Enhanced formulations show promise in preclinical studies, but human pharmacokinetic validation is needed.

Key Research Facts

1

Fisetin's oral bioavailability is estimated at less than 10%, making it one of the most challenging dietary flavonoids for oral delivery.

Strong Evidence

Grynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159

2

Fisetin has poor aqueous solubility (~10.45 μg/mL), classifying it as BCS Class IV (low solubility, low permeability).

Strong Evidence

Grynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159

3

Rapid phase II metabolism (glucuronidation and sulfation) in the intestinal wall and liver converts most oral fisetin to conjugated metabolites before systemic circulation.

Strong Evidence

Grynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159

4

Liposomal fisetin formulations showed 3–5× improved bioavailability compared to standard fisetin in rodent pharmacokinetic studies.

Moderate Evidence

Pharmaceutical research — Formulation studies review

5

Nanoparticle-based delivery systems (PLGA, chitosan, solid lipid nanoparticles) showed 4–10× bioavailability improvements in animal models.

Moderate Evidence

Drug delivery research — Grynkiewicz & Demchuk, 2019

6

Cell culture experiments showing senolytic activity use fisetin at 10–100 μM — concentrations that may be unachievable through oral supplementation.

Strong Evidence

Yousefzadeh et al., EBioMedicine — doi:10.1016/j.ebiom.2018.09.015

7

No enhanced fisetin formulation has been validated in a published human randomized controlled trial as of 2026.

Strong Evidence

Literature review — PubMed search, 2026

8

The discrepancy between in vitro effective concentrations and achievable in vivo plasma levels is the central translational challenge for fisetin research.

Strong Evidence

Pharmacokinetic analysis — Grynkiewicz & Demchuk, 2019

9

Whether fisetin metabolites (glucuronides, sulfates) retain meaningful senolytic or anti-inflammatory activity remains an open research question.

Emerging Evidence

Metabolite activity research — Khan et al., 2013

10

Human pharmacokinetic studies with specific fisetin formulations are needed to bridge the gap between preclinical promise and clinical application.

Strong Evidence

Research gap analysis — Literature review

Continue Your Research

Explore related topics and take the next step in your cellular health journey.

Citations & External Resources

Clinical Registry

ClinicalTrials.gov — Search: Fisetin

Review

PubMed — Fisetin research

Review

EBioMedicine — Yousefzadeh et al. 2018 (Landmark Senolytic Study)

Clinical Registry

NCT06133634 — Fisetin Vascular Function Trial

Review

Antioxidants & Redox Signaling — Khan et al. 2013 (Comprehensive Review)

Review

Frontiers in Chemistry — Grynkiewicz & Demchuk 2019 (Bioavailability)

Warning: Your Mitochondria Are Dying 1% Every Year After 40

Here's what thousands of people over 45 are doing about it — a simple daily protocol based on cutting-edge cellular science.

Related Reading

References (3)

Written by

ReCellence™ Editorial Team

Health Content Specialists

Medically reviewed by

Medical Review Board

MD, PhD

Last updated: March 8, 2026

Last medical review: March 8, 2026